Evidence map›Paper›PMID 38903931›Full record

ArticleInternational journal of medical sciences2024

FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer.

Zhengnan Huang, Zeyi Wang, Chengdang Xu, Yilin Yan, Xiangqian Cao, Fang Zhang, Bing Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhengnan HuangDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Zeyi WangDepartment of Urology, Huadong Hospital, Fudan University, Shanghai, China. 200040, China.
Chengdang XuDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Yilin YanDepartment of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China.
Xiangqian CaoDepartment of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China.
Fang ZhangDepartment of Urology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China.
Bing ShenDepartment of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorFibrinogenGene Expression Regulation, NeoplasticImmunotherapyUrinary Bladder NeoplasmsAgedDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNomogramsPrognosisTumor MicroenvironmentBiomarkers, TumorFGL2 protein, humanFibrinogenbladder cancerFGL2immunotherapyprognosistumor microenvironment.

Identifiers

PMID38903931
PMCPMC11186416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.